ObsEva SA (OBSV) Bundle
A Brief History of ObsEva SA (OBSV)
Company Overview
ObsEva SA is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Geneva, Switzerland. The company focuses on developing and commercializing novel therapies for reproductive health and pregnancy-related conditions. Its primary aim is to address significant unmet medical needs in these areas.
Founding and Initial Funding
ObsEva was co-founded by Dr. Julian C. S. H. E. Dufour, Dr. Michel de Wildt, and Dr. Jeffrey A. M. Brandt. In 2014, the company completed a Series A financing round, raising approximately $22.5 million. The proceeds were used to advance its clinical programs and build its pipeline.
Clinical Pipeline Development
ObsEva's pipeline includes several candidate drugs aimed at treating various conditions:
- OBE022: A selective oral prostaglandin antagonist targeting endometriosis.
- OBE001: A treatment for preterm labor and pregnancy complications.
- OBE201: A potential therapy for polycystic ovary syndrome (PCOS).
Public Offering
In March 2017, ObsEva completed an initial public offering (IPO) on the Nasdaq Global Market under the ticker symbol OBSV. The IPO raised about $75 million at an offering price of $15 per share.
Key Milestones and Collaborations
Throughout its history, ObsEva has secured various collaborations and partnerships:
- In 2018, the company entered a $100 million licensing agreement with a leading pharmaceutical firm for OBE022.
- In 2019, ObsEva partnered with Mayne Pharma for a co-development agreement related to OBE001.
Recent Financial Performance
As of the second quarter of 2023, ObsEva reported revenue of $3.4 million, primarily from collaborations and licensing agreements. The total operating expenses for the same period were approximately $10.5 million, with a net loss of around $7.1 million.
Stock Performance
ObsEva's stock performance on NASDAQ has shown significant variability. As of October 2023, the company’s share price was approximately $2.10, reflecting a market capitalization of around $37 million.
Recent Developments
In 2023, ObsEva announced the completion of Phase 3 trials for OBE022, with results showing significant efficacy in patients with endometriosis. The company plans to submit a New Drug Application (NDA) to the FDA in early 2024.
| Year | Funding ($ millions) | Revenue ($ millions) | Net Loss ($ millions) | Share Price ($) |
|---|---|---|---|---|
| 2014 | 22.5 | - | - | - |
| 2017 | 75 | - | - | 15 |
| 2023 | - | 3.4 | 7.1 | 2.10 |
Future Outlook
ObsEva continues to focus on advancing its pipeline and exploring additional strategic partnerships to enhance its market position in women's health therapeutics. The upcoming NDA submission and Phase 3 trial results are expected to play a significant role in shaping the company's future growth.
A Who Owns ObsEva SA (OBSV)
Ownership Structure
Ownership Structure
The ownership structure of ObsEva SA (OBSV) consists of institutional investors, retail investors, and company insiders. As of the latest filings, the following ownership percentages are noted:
| Owner Type | Percentage Owned | Number of Shares |
|---|---|---|
| Institutional Investors | 66.5% | 10,200,000 |
| Retail Investors | 18.3% | 2,800,000 |
| Company Insiders | 15.2% | 2,300,000 |
Major Shareholders
Key institutional shareholders and their respective holdings are as follows:
| Shareholder | Type | Shares Owned | Percentage Owned |
|---|---|---|---|
| BlackRock, Inc. | Institutional | 1,500,000 | 9.5% |
| Baker Bros. Advisors LP | Institutional | 1,200,000 | 7.6% |
| FMR LLC | Institutional | 1,000,000 | 6.3% |
| Invesco Ltd. | Institutional | 800,000 | 5.1% |
| Vanguard Group Inc. | Institutional | 700,000 | 4.4% |
Insider Ownership
Insider ownership comprises executive team members and board members. The following table summarizes their stakes:
| Name | Position | Shares Owned | Percentage Owned |
|---|---|---|---|
| Dr. Dror Ben-Asher | CEO | 500,000 | 3.2% |
| Dr. Patrick Flanigan | Chief Medical Officer | 400,000 | 2.5% |
| David C. Mott | Board Member | 300,000 | 1.9% |
| Dr. Michael H. Steinmetz | Board Member | 200,000 | 1.3% |
Recent Financial Data
As of the most recent earnings report, ObsEva SA has provided the following financial highlights:
- Total Revenue (2022): $15.5 million
- Net Loss (2022): $35.2 million
- Cash Position (End of Q2 2023): $25 million
- Market Capitalization (as of October 2023): $85 million
Share Performance
Share performance metrics for ObsEva SA as of October 2023 are as follows:
| Metric | Value |
|---|---|
| Current Share Price | $4.20 |
| 52-Week High | $6.50 |
| 52-Week Low | $2.50 |
| Year-to-Date Performance | +15% |
ObsEva SA (OBSV) Mission Statement
Core Mission
Core Mission
ObsEva SA is dedicated to developing innovative therapies for women's health, particularly in areas with significant unmet medical needs. The company aims to enhance the quality of life for women through effective and safe treatment options.
Strategic Goals
- Advance clinical development programs focused on reproductive health.
- Leverage scientific expertise to create breakthrough medicines.
- Commit to sustainable practices and ethical standards in research and development.
Focus Areas
The company primarily focuses on:
- Endometriosis
- Uterine fibroids
- Infertility
Current Pipeline Overview
ObsEva’s pipeline includes:
| Product Candidate | Indication | Stage of Development | Expected Milestones |
|---|---|---|---|
| OBE022 | Endometriosis | Phase 3 | Top-line results expected Q4 2023 |
| OBE001 | Uterine Fibroids | Phase 2 | Initiation of Phase 3 trials planned in 2024 |
| OBE022 | Infertility | Phase 2 | Data readout anticipated in 2024 |
Financial Overview
As of Q3 2023, ObsEva reported financial metrics as follows:
| Metric | Q3 2023 Amount | Year-over-Year Change |
|---|---|---|
| Total Revenue | $5.2 million | +12% |
| Operating Expenses | $12.9 million | -8% |
| Cash and Cash Equivalents | $36.4 million | +15% |
Commitment to Innovation
ObsEva is focused on leveraging cutting-edge research and collaborative partnerships to expedite the development of its product candidates, aiming to meet the pressing needs of women's health.
Values and Culture
The company’s core values include:
- Integrity in all operations
- Collaboration among multidisciplinary teams
- Commitment to patients and their families
Future Outlook
Looking ahead, ObsEva is positioned to make significant contributions to women’s health by bringing forward innovative treatments and maintaining strong financial health for sustainable growth.
How ObsEva SA (OBSV) Works
Company Overview
Company Overview
ObsEva SA, a biopharmaceutical company headquartered in Geneva, Switzerland, is focused on developing and commercializing novel therapies to improve women's health. The company primarily targets areas such as endometriosis, uterine fibroids, and preterm labor.
Financial Performance
As of Q2 2023, ObsEva reported a total revenue of $2.8 million, derived from product sales and collaborations.
The company's total assets stood at $84.5 million, while total liabilities were reported at $33.2 million, resulting in a total equity of $51.3 million.
| Metric | Value (Q2 2023) |
|---|---|
| Total Revenue | $2.8 million |
| Total Assets | $84.5 million |
| Total Liabilities | $33.2 million |
| Total Equity | $51.3 million |
Key Products
ObsEva's lead product candidates include:
- Elagolix: A novel oral therapy for treating endometriosis and uterine fibroids.
- O-157: A treatment for preterm labor.
- OBE022: In development for endometriosis.
Market Strategy
The company's strategy involves targeting unmet medical needs in women's health and establishing partnerships with other pharmaceutical companies to enhance its development pipeline.
Research and Development
As of 2023, ObsEva has invested approximately $50 million in R&D. The company has ongoing clinical trials for its lead product candidates:
- Phase 3 trials for Elagolix.
- Phase 2 trials for OBE022.
Partnerships and Collaborations
ObsEva has established collaborations with various pharmaceutical companies and research institutions, aiming to accelerate the development of its product portfolio.
| Partnership | Type | Focus Area |
|---|---|---|
| Partner A | Research Collaboration | Female Reproductive Health |
| Partner B | Development Agreement | Endometriosis |
Recent Developments
In 2023, ObsEva obtained regulatory approval for Elagolix in the European market, expanding its commercial reach. The company is also preparing for the launch of its next-generation therapy aimed at uterine fibroids.
Outlook and Projections
For the fiscal year 2023, ObsEva projects a revenue increase of 20% year-over-year, driven by expanded market access and increased demand for its therapies.
How ObsEva SA (OBSV) Makes Money
Revenue Generation
ObsEva SA primarily generates revenue through the development and commercialization of innovative therapies aimed at women's health. The company's focus is on addressing unmet medical needs in reproductive health, primarily through its investigational product candidates.
Key Products and Pipeline
ObsEva’s leading product candidates include:
- Elagolix: An oral GnRH antagonist for the treatment of endometriosis.
- OBE022: A treatment for preterm labor and chronic gynecological conditions.
- OBE001: A potential treatment for infertility.
| Product | Indication | Stage of Development | Estimated Market Size (USD billion) |
|---|---|---|---|
| Elagolix | Endometriosis | Commercialized | 2.5 |
| OBE022 | Preterm Labor | Phase 2 | 1.0 |
| OBE001 | Infertility | Phase 2 | 2.0 |
Partnerships and Collaborations
ObsEva actively engages in strategic partnerships to enhance its revenue potential. These partnerships often include:
- Licensing Agreements with larger pharmaceutical companies.
- Joint Ventures for co-development of products.
Financials
As of Q3 2023, ObsEva reported the following financial metrics:
| Metric | Amount (USD million) |
|---|---|
| Total Revenue | 20.5 |
| Net Income (Loss) | (12.3) |
| R&D Expenses | 18.7 |
| Operating Expenses | 15.2 |
| Cash and Cash Equivalents | 45.0 |
Market Position and Competition
ObsEva operates in a competitive environment where it faces numerous challenges and opportunities. The following are notable competitors in the women's health market:
- AbbVie
- Pfizer
- Ferring Pharmaceuticals
Future Growth Opportunities
ObsEva’s future revenue growth is anticipated from:
- Expanding clinical trials for existing products.
- New product development targeting women's health.
| Upcoming Milestone | Expected Date | Description |
|---|---|---|
| Phase 3 Results for Elagolix | Q2 2024 | Potential for market approval. |
| New Indication for OBE022 | Q4 2024 | Exploration of additional gynecological disorders. |
ObsEva SA (OBSV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support